A Phase 4 interventional study of Oral Acetaminophen and IV Acetaminophen in Pain, sponsored by Mallinckrodt. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Mallinckrodt · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 94th largest by enrollment, is one of 9 that started in 2016, is one of 67 in phase 4, and was the 93rd registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
16 studies in Pain by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 16 studies in Pain by Keenova Therapeutics plc, this one is the 12th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 4, and was the 16th registered.
Keenova Therapeutics plc’s Pain studies by the year they started, since 2001.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 16 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Morphine is the opioid used to treat pain after surgery. Acetaminophen (called APAP) can reduce the amount of opioids needed for this.
The problem is that morphine slows down digestion. That can delay pain relief from APAP pills. It can even change what the body does to the drug [pharmacokinetics (PK)].
Some doctors have started using intravenous (IV) APAP with morphine, instead of the pills.
This study will measure the PK of APAP pills and IV when used with morphine in healthy volunteers.
IV APAP will likely be more effective and cause fewer side effects when used with morphine to treat pain after surgery.
Acetaminophen can significantly reduce the use of opioid analgesics when both are used concomitantly for treating moderate to severe pain. The use of IV acetaminophen used concomitantly with opioids has increased in practice for postsurgical pain relief over orally administered acetaminophen because it provides an immediate peak plasma concentration and is believed to provide a faster analgesic effect. Opioids used to treat pain inhibit gastrointestinal motility, including delaying gastric emptying. In patients receiving opioids the absorption of orally administered acetaminophen may be delayed and could result in gastric accumulation of acetaminophen thereby markedly changing the pharmacokinetic profile. The opioid-induced inhibition of gastrointestinal motility would not be expected to affect IV acetaminophen pharmacokinetics. Thus coadministered IV acetaminophen with opioid would yield better outcome in efficacy and reduced risk of side effects comparing with coadministration of oral acetaminophen and opioids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
Drug: Oral Acetaminophen · Drug: IV Morphine · Drug: Saline
Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
Drug: IV Acetaminophen · Drug: IV Morphine · Drug: Placebo Tablets
Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
Also known as: APAP Oral
Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
Also known as: APAP IV
Morphine for IV administration (0.125 mg/kg)
Placebo tablets matching oral acetaminophen
Saline placebo matching IV acetaminophen
Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen
The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration
Time frame: hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration
Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration
AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration
Time frame: hours 0-18 during treatment with each mode of acetaminophen administration
Maximum Concentration (Cmax) of Acetaminophen
Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.
Time frame: hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration
Time to Maximum Concentration (Tmax) of Acetaminophen
Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.
Time frame: hours -6 to 0, 0-6, 6-12 and 12-18 during treatment with each mode of acetaminophen administration
| Milestone | Oral Acetaminophen | IV Acetaminophen |
|---|---|---|
| Started | 27 | 23 |
| Per protocol population | 11 | 11 |
| Safety population | 27 | 23 |
| Completed | 11 | 12 |
| Not completed | 16 | 11 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Emesis | 15 | 11 |
The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration
| hour*microgram per milliliter (h*mcg/mL) | First Dose - Before Morphine Co-administration | Second Dose - During Morphine Co-administration | Third Dose - During Morphine Co-administration | Fourth Dose - After Morphine Co-administration |
|---|---|---|---|---|
| Treatment A: Oral Acetaminophen | 31.00 ± 5.11 | 28.51 ± 5.96 | 25.31 ± 11.59 | 52.38 ± 13.48 |
| Treatment B: IV Acetaminophen | 42.56 ± 3.94 | 44.37 ± 4.46 | 43.59 ± 4.21 | 49.05 ± 3.95 |
AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration
| hour*microgram per milliliter (h*mcg/mL) | After First Dose of Morphine Co-administration |
|---|---|
| Treatment A: Oral Acetaminophen | 82.50 ± 23.28 |
| Treatment B: IV Acetaminophen | 63.58 ± 6.74 |
Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.
| mcg/mL | First Dose - Before Morphine Co-administration | Second Dose - During Morphine Co-administration | Third Dose - During Morphine Co-administration | Fourth Dose - After Morphine Co-administration |
|---|---|---|---|---|
| Treatment A: Oral Acetaminophen | 11.6 ± 4.11 | 7.29 ± 1.82 | 7.25 ± 3.95 | 13.5 ± 3.31 |
| Treatment B: IV Acetaminophen | 22.6 ± 3.83 | 17.0 ± 1.48 | 17.5 ± 1.93 | 28.5 ± 4.31 |
Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.
| hours | First Dose - Before Morphine Co-administration | Second Dose - During Morphine Co-administration | Third Dose - During Morphine Co-administration | Fourth Dose - After Morphine Co-administration |
|---|---|---|---|---|
| Oral Acetaminophen | 1.48 (0.75 to 2.02) | 1.64 (0.50 to 3.00) | 3.26 (0.50 to 5.85) | 2.84 (1.17 to 4.02) |
| IV Acetaminophen | 0.25 (0.25 to 0.27) | 0.50 (0.50 to 0.50) | 0.51 (0.50 to 0.57) | 0.25 (0.25 to 0.28) |
Collected over From start of the study to the end of study (approximately 2 weeks, including wash-out period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Acetaminophen | 0/27 (0%) | 0/27 (0%) | 22/27 (81.5%) |
| IV Acetaminophen | 0/23 (0%) | 0/23 (0%) | 17/23 (73.9%) |
| Event | Oral Acetaminophen | IV Acetaminophen |
|---|---|---|
| VomitingGastrointestinal disorders | 15/27 | 11/23 |
| NauseaGastrointestinal disorders | 12/27 | 10/23 |
| DizzinessNervous system disorders | 4/27 | 4/23 |
| SomnolenceNervous system disorders | 4/27 | 1/23 |
| Euphoric moodPsychiatric disorders | 1/27 | 3/23 |
| HeadacheNervous system disorders | 2/27 | 2/23 |
| ParaesthesiaNervous system disorders | 1/27 | 2/23 |
| PruritusSkin and subcutaneous tissue disorders | 2/27 | 2/23 |
| AstheniaGeneral disorders | 2/27 | 0/23 |
| Catheter site painGeneral disorders | 2/27 | 0/23 |
All participants with emesis were removed from the study, with no replacement. Because 7 of 9 females had emesis at the first dose, an amendment was written to exclude females. Therefore, demographics are provided for the per protocol population.
| Age, Continuous(years) | Oral Acetaminophen | IV Acetaminophen | Total |
|---|---|---|---|
| Mean | 33.1 ± 9.82 | 32.5 ± 11.25 | 32.8 ± 10.31 |
| Sex: Female, Male(Participants) | Oral Acetaminophen | IV Acetaminophen | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 11 | 10 | 21 |
| Race/Ethnicity, Customized(Participants) | Oral Acetaminophen | IV Acetaminophen | Total |
|---|---|---|---|
| White | 7 | 9 | 16 |
| Black or African American | 2 | 2 | 4 |
| Hispanic or Latino Ethnicity | 4 | 6 | 10 |
| Not Hispanic or Latino | 7 | 5 | 12 |
Plan to share: No
Ran from Feb 2016 to primary completion in Mar 2016, 1 month.
Results were first posted in Jan 2020, 3 years 10 months after primary completion.
Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Morphine